Evidence map›Paper›PMID 40070570›Full record

ReviewFrontiers in pharmacology2025

Association between

Asmaa Ibrahim, Kazeem Yusuff, Ahmed Awaisu, Hazem Elewa

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Tetracycline for Helicobacter pylori eradication: a narrative review from quadruple to dual therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Asmaa IbrahimDepartment of Clinical Pharmacy and Practice, College of Pharmacy, Qatar University, Doha, Qatar.
Kazeem Yusuff *Department of Clinical Pharmacy and Practice, College of Pharmacy, Qatar University, Doha, Qatar.
Ahmed Awaisu *Department of Clinical Pharmacy and Practice, College of Pharmacy, Qatar University, Doha, Qatar.
Hazem Elewa *Department of Clinical Pharmacy and Practice, College of Pharmacy, Qatar University, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proton pump inhibitors (PPIs) are widely prescribed medications for the management of acid-related disorders, due to their effectiveness and favorable pharmacokinetics. However, the occurrence and severity of adverse drug reactions (ADRs) in patients using PPIs, particularly in relation to their association with

Indexed as

adverse drug reactionsCYP2C19 polymorphismoveruse and misusepharmacogenomics (PGx)proton pump inhibitors

Identifiers

PMID40070570
PMCPMC11894441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.